Glial Glutamate Transporter Modulation Prevents Development of Complete Freund’s Adjuvant-Induced Hyperalgesia and Allodynia in Mice
Open Access
- 16 May 2023
- journal article
- research article
- Published by MDPI AG in Brain Sciences
- Vol. 13 (5) , 807
Abstract
Glial glutamate transporter (GLT-1) modulation in the hippocampus and anterior cingulate cortex (ACC) is critically involved in nociceptive pain. The objective of the study was to investigate the effects of 3-[[(2-methylphenyl) methyl] thio]-6-(2-pyridinyl)-pyridazine (LDN-212320), a GLT-1 activator, against microglial activation induced by complete Freund’s adjuvant (CFA) in a mouse model of inflammatory pain. Furthermore, the effects of LDN-212320 on the protein expression of glial markers, such as ionized calcium-binding adaptor molecule 1 (Iba1), cluster of differentiation molecule 11b (CD11b), mitogen-activated protein kinases (p38), astroglial GLT-1, and connexin 43 (CX43), were measured in the hippocampus and ACC following CFA injection using the Western blot analysis and immunofluorescence assay. The effects of LDN-212320 on the pro-inflammatory cytokine interleukin-1β (IL-1β) in the hippocampus and ACC were also assessed using an enzyme-linked immunosorbent assay. Pretreatment with LDN-212320 (20 mg/kg) significantly reduced the CFA-induced tactile allodynia and thermal hyperalgesia. The anti-hyperalgesic and anti-allodynic effects of LDN-212320 were reversed by the GLT-1 antagonist DHK (10 mg/kg). Pretreatment with LDN-212320 significantly reduced CFA-induced microglial Iba1, CD11b, and p38 expression in the hippocampus and ACC. LDN-212320 markedly modulated astroglial GLT-1, CX43, and, IL-1β expression in the hippocampus and ACC. Overall, these results suggest that LDN-212320 prevents CFA-induced allodynia and hyperalgesia by upregulating astroglial GLT-1 and CX43 expression and decreasing microglial activation in the hippocampus and ACC. Therefore, LDN-212320 could be developed as a novel therapeutic drug candidate for chronic inflammatory pain.Keywords
Funding Information
- the South Dakota State University (SDSU) Research Foundation (SR), Department of Pharmaceutical Sciences of SDSU (I01BX00471, NIMH R01 MH122954, NIH NIGMS U54GM128729)
- College of Pharmacy (SR) (I01BX00471, NIMH R01 MH122954, NIH NIGMS U54GM128729)
- Department of Veterans Affairs Merit Review Award (I01BX00471, NIMH R01 MH122954, NIH NIGMS U54GM128729)
This publication has 107 references indexed in Scilit:
- Deconstructing the Neuropathic Pain Phenotype to Reveal Neural MechanismsNeuron, 2012
- GLT-1 overexpression attenuates bladder nociception and local/cross-organ sensitization of bladder nociceptionAmerican Journal of Physiology-Renal Physiology, 2011
- Microglial/macrophage GRK2 determines duration of peripheral IL-1β-induced hyperalgesia: Contribution of spinal cord CX3CR1, p38 and IL-1 signalingPain, 2010
- Spinal upregulation of glutamate transporter GLT-1 by ceftriaxone: therapeutic efficacy in a range of experimental nervous system disordersNeuroscience, 2010
- β-Lactam antibiotic produces a sustained reduction in extracellular glutamate in the nucleus accumbens of ratsAmino Acids, 2010
- Central Sensitization: A Generator of Pain Hypersensitivity by Central Neural PlasticityThe Journal of Pain, 2009
- A quantitative assessment of glutamate uptake into hippocampal synaptic terminals and astrocytes: New insights into a neuronal role for excitatory amino acid transporter 2 (EAAT2)Neuroscience, 2008
- IL-1ra alleviates inflammatory hyperalgesia through preventing phosphorylation of NMDA receptor NR-1 subunit in ratsPain, 2008
- Propentofylline-induced astrocyte modulation leads to alterations in glial glutamate promoter activation following spinal nerve transectionNeuroscience, 2008
- Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic painNature Medicine, 2008